Interpace Biosciences earnings release, May 14, 2026

Interpace Biosciences, Inc. (IDXG) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Interpace

Biosciences Announces First Quarter 2026 Financial and Business Results

PARSIPPANY,

NJ, May 12, 2026 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX:

IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations, and produced Adjusted EBITDA of $1.6 million, or 17% of revenue.

“Our first quarter results demonstrate continued momentum in our thyroid franchise and the operational efficiency that has come with our transition to a thyroid-only diagnostics testing company,” said Chris McCarthy, Chief Financial Officer. “Q1 2026 thyroid revenue increased

12% year-over-year and gross margin expanded to 65% from 59% on a Pro Forma basis. Adjusted EBITDA improved to $1.6 million from $0.8 million in the prior year quarter on a Pro Forma basis. Operating income margin improved to 12% from 6% in the prior year quarter on a Pro Forma basis and adjusted EBITDA margin improved to 17% from 10% in the prior year quarter on a Pro Forma basis. These results reflect the strength of our ThyGeNEXT® and ThyraMIR® v2 platform and the consistent execution of our commercial team.”

McCarthy added, “Our debt-free balance sheet continues to support meaningful investment in laboratory automation and AI-enabled productivity initiatives across our workflow. We are scaling operating leverage in line with volume growth without a corresponding increase in headcount, which we expect will support continued margin expansion as the year progresses.”

“The first quarter demonstrates the durability of the business we built through last year’s transition and positions Interpace to build on this momentum through the remainder of 2026.” said Tom Burnell, President and CEO. “We see the same characteristics in

Q1 2026 that defined our 2025 performance — disciplined execution, expanding clinical adoption, and a steady cadence of operational improvement. We continue to believe our combination approach — ThyGeNEXT® for mutation detection and ThyraMIR® v2 for microRNA pathway insights — gives physicians the confidence and clarity they need to make informed patient-management decisions.”

Outlook

With a streamlined, thyroid-only operating model and continued commercial momentum, Interpace is positioned to build on its first-quarter performance through the remainder of 2026. The Company is reaffirming its previously provided 2026 guidance of approximately 16% year-over-year thyroid revenue growth, and remains focused on scaling thyroid test volume through deeper adoption within existing accounts, expanding the active account base, and driving productivity gains through laboratory automation and operational discipline.

Business

Highlights

First

Quarter 2026 Financial Performance

For the First Quarter of 2026 as Compared to the First Quarter of 2025 and Pro Forma 2025 Results:

Management uses a non-GAAP Pro Forma income statement to help evaluate the results of our performance. The Pro Forma income statement for 2025 reflects the Company’s current business structure as a thyroid-only diagnostics testing company and excludes revenue and related costs from

PancraGEN, which was discontinued in May 2025. These adjustments are presented for comparability purposes only and do not represent GAAP financial measures. Investors should review GAAP results alongside these pro forma figures for a complete understanding of performance.

A reconciliation of GAAP and these pro forma figures is presented below.

About

Interpace Biosciences

Interpace

Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.

Interpace has two commercialized molecular tests: ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIR® v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – March 31, – 2026 – (unaudited)Three Months Ended – March 31, – 2025 – (unaudited)
Revenue, net9,03211,515
Cost of revenue3,1284,145
Gross Profit5,9047,370
Sales and marketing2,1772,814
Research and development153177
General and administrative2,4512,550
Total operating expenses4,7815,541
Operating income1,1231,829
Note payable interest expense-78
Other income, net1021
Income from continuing operations before tax1,1331,772
Provision for income taxes30218
Income from continuing operations8311,754
Loss from discontinued operations, net of tax-110-107
Net income7211,647
Basic income (loss) per share of common stock:From continuing operations0.040.4
Basic income (loss) per share of common stock:From discontinued operations-0.01-0.03
Basic income (loss) per share of common stock:Net income (loss) per basic share of common stock0.030.37
Diluted income (loss) per share of common stock:From continuing operations0.030.06
Diluted income (loss) per share of common stock:From discontinued operations00
Diluted income (loss) per share of common stock:Net income (loss) per diluted share of common stock0.030.06
Weighted average number of common shares and common share equivalents outstanding:Basic22,7864,420
Weighted average number of common shares and common share equivalents outstanding:Diluted27,70727,704

Income Statement

Three Months Ended March 31, 2025 — (in thousands, except per share data)

Three Months Ended March 31, 2025 – As ReportedThree Months Ended March 31, 2025 – PancraGEN – Direct Costs*Three Months Ended March 31, 2025 – Pro Forma
Revenue, net11,5153,5947,921
Cost of revenue4,1459403,205
Gross Profit7,3702,6544,716
Sales and marketing2,8141,1661,648
Research and development17770107
General and administrative2,550932,457
Total operating expenses5,5411,3294,212
Operating income1,8291,325504
Note payable interest-78-78
Other income, net2121
Income from continuing operations before tax1,7721,325447
Provision for income taxes1818
Income from continuing operations1,7541,325429
Loss from discontinued operations, net of tax-107-107
Net income1,6471,325322
Basic income (loss) per share of common stock:From continuing operations0.40.30.1
Basic income (loss) per share of common stock:From discontinued operations-0.03-0.03
Basic income (loss) per share of common stock:Net income (loss) per basic share of common stock0.370.30.07
Diluted income (loss) per share of common stock:From continuing operations0.060.050.01
Diluted income (loss) per share of common stock:From discontinued operations00
Diluted income (loss) per share of common stock:Net income (loss) per diluted share of common stock0.060.050.01
Weighted average number of common shares and common share equivalents outstanding:Basic4,4204,4204,420
Weighted average number of common shares and common share equivalents outstanding:Diluted27,70427,70427,704

Income Statement

Three Months Ended — ($ in thousands)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Income from continuing operations (GAAP Basis)8311,754
Depreciation and amortization11895
Stock-based compensation415
Severance & related expense168
Income tax expense30218
Non-recurring legal expense315
Note payable interest78
Interest income-10-7
Change in fair value of note payable-25
Adjusted EBITDA1,5602,096

Balance Sheet

December 31, — ($ in thousands)

March 31, – 2026December 31, – 2025
Cash and cash equivalents2,6472,505
Total current assets9,9639,900
Total current liabilities3,9625,103
Total assets33,40933,838
Total liabilities10,32711,475
Total stockholders’ equity23,08222,363

Cash Flow

For the Three Months Ended — ($ in thousands)

For the Three Months Ended – March 31, – 2026For the Three Months Ended – March 31, – 2025
Net income7211,647
Net cash provided by operating activities2831,235
Net cash used in investing activities-141
Net cash used in financing activities-1,500
Change in cash and cash equivalents142-265
Cash and cash equivalents – beginning2,5051,461
Cash and cash equivalents – ending2,6471,196
Full release

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the

Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,”

“estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,”

“potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may... (truncated) statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, net income and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, and the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect.

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual

Report on Form 10-K for the fiscal year ended December 31, 2025, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts

Investor

Relations

Interpace

Biosciences, Inc.

(855)-776-6419

Info@Interpace.com

INTERPACE

BIOSCIENCES, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Interpace Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.